← Leaderboards
Rahul Aggarwal
University Of California, San Francisco
$5,953,056
Attributed
$14,673,187
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,673,187 · 7
By mechanism
R01$14,673,187 · 7
Top collaborators
- Michael John Evans8 shared
- Charles Scott Craik7 shared
- John Kurhanewicz5 shared
- Daniel B Vigneron5 shared
- Robert Richard Flavell4 shared
- Lawrence Fong4 shared
- Henry F. Vanbrocklin4 shared
- Thomas Hope2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Michael John Evans$10,372,266
- Thomas Hope$3,566,163
- Robert Richard Flavell$4,877,416
- Charles Scott Craik$31,131,909
- Felix Yi-Chung Feng$6,764,664
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseCancer PatientDetectionImageBiological MarkersPositron-Emission TomographyMediatingNeoplasm MetastasisTumorBiopsyMalignant NeoplasmsMeasurementPre-ClinicalSiteMalignant Neoplasm Of ProstateCohortCancer ModelImaging ApproachResistanceSafetyToxic EffectUptakeTreatment ResponseNovel Strategies
Grant awards (24)
Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe$669,794
R01 · FY2025 · CA
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring$669,724
R01 · FY2025 · CA
Precision targeting of T cell cytotoxicity with PET$643,445
R01 · FY2025 · CA
Molecular imaging of novel PARP inhibitor nanomedicine delivery$621,383
R01 · FY2025 · CA
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring$636,237
R01 · FY2024 · CA
Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe$616,174
R01 · FY2024 · CA
Precision targeting of T cell cytotoxicity with PET$611,272
R01 · FY2024 · CA
Molecular imaging of novel PARP inhibitor nanomedicine delivery$590,313
R01 · FY2024 · CA
Combining immunotherapy with molecularly targeted radiation therapy$663,343
R01 · FY2023 · CA
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring$656,329
R01 · FY2023 · CA
Precision targeting of T cell cytotoxicity with PET$635,683
R01 · FY2023 · CA
Molecular imaging of novel PARP inhibitor nanomedicine delivery$589,327
R01 · FY2023 · CA
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring$656,329
R01 · FY2022 · CA
Precision targeting of T cell cytotoxicity with PET$652,933
R01 · FY2022 · CA
Molecular imaging of novel PARP inhibitor nanomedicine delivery$576,944
R01 · FY2022 · CA
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring$669,448
R01 · FY2021 · CA
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring$655,889
R01 · FY2021 · CA
Precision targeting of T cell cytotoxicity with PET$524,205
R01 · FY2021 · CA
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring$655,889
R01 · FY2020 · CA
Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer$368,455
R01 · FY2020 · CA · contact PI
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring$637,566
R01 · FY2019 · CA
Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer$366,367
R01 · FY2019 · CA · contact PI
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring$656,096
R01 · FY2018 · CA
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring$650,042
R01 · FY2017 · CA